By Sam Boughedda
Investing.com -- Caredx Inc (NASDAQ:CDNA) announced Monday evening that the company has won its false advertising case against Natera Inc (NASDAQ:NTRA).
CareDx won $44.9 million in damages. Shares rose 8.8% after the announcement.
The jury determined that Natera intentionally misled the transplant community by engaging in false advertising and promoting its Prospera kidney transplant rejection assessment test.
CareDx was awarded $21.2 million compensatory damages and $23.7 million punitive damages. CareDx said "overwhelming evidence" emerged that Natera's senior executives knew of the unscientific and unreliable statements made to market Prospera.
"The jury found Natera liable for false advertising based on Natera's false comparisons of its kidney transplant assessment test, Prospera, to CareDx's market-leading AlloSure technology," CareDx said in its press release.
Natera stock is down 16%.